Trends in Botulinum Toxin-Related Industry Payments to Physicians.

IF 1.6 3区医学 Q2 SURGERY

Facial Plastic Surgery & Aesthetic Medicine Pub Date : 2024-09-01 Epub Date: 2024-03-26 DOI:10.1089/fpsam.2023.0198

Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan

{"title":"Trends in Botulinum Toxin-Related Industry Payments to Physicians.","authors":"Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan","doi":"10.1089/fpsam.2023.0198","DOIUrl":null,"url":null,"abstract":"Objectives: To evaluate trends in botulinum toxin (BTX) industry payments to physicians. Methods: Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. Results: Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8.7 million in 2019. 21.7% was paid to dermatologists, 57.5% to neurologists, 5.9% to ophthalmologists, 5.7% to otolaryngologists, and 9.1% to plastic surgeons. Conclusions: Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.","PeriodicalId":48487,"journal":{"name":"Facial Plastic Surgery & Aesthetic Medicine","volume":" ","pages":"512-516"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Facial Plastic Surgery & Aesthetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/fpsam.2023.0198","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To evaluate trends in botulinum toxin (BTX) industry payments to physicians. Methods: Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. Results: Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8.7 million in 2019. 21.7% was paid to dermatologists, 57.5% to neurologists, 5.9% to ophthalmologists, 5.7% to otolaryngologists, and 9.1% to plastic surgeons. Conclusions: Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.

查看原文本刊更多论文

肉毒杆菌毒素相关行业向医生支付费用的趋势。

目的：评估肉毒杆菌毒素 (BTX) 行业向医生支付费用的趋势。方法：横向分析 Allergan 公司（肉毒杆菌毒素）和 BTX 公司（肉毒杆菌毒素）向医生支付的非特许权使用费：使用 2016-2020 年开放支付数据库，对 Allergan（Botox）、Ipsen（Dysport）和 Merz（Xeomin）向医生支付的非特许权使用费、特定 BTX 付款进行横截面分析。结果：2016 年至 2020 年间，皮肤科医生、神经科医生、眼科医生、耳鼻喉科医生和整形外科医生因 BTX 相关活动而获得的付款超过 2700 万美元，付款额从 2016 年的 390 万美元到 2019 年的 870 万美元不等。其中 21.7% 支付给皮肤科医生，57.5% 支付给神经科医生，5.9% 支付给眼科医生，5.7% 支付给耳鼻喉科医生，9.1% 支付给整形外科医生。结论：支付给医生的 BTX 相关活动（包括医疗和美容）的费用越来越多。尽管 BTX 在耳鼻咽喉科的适应症多种多样，但耳鼻咽喉科的付费却被其他专科所掩盖，这可能反映出这些专科对 BTX 的使用率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊